Why the study?
Cancer-associated thrombosis poses management challenges, and while LMWH is standard of care, its cost and daily injections lead to low persistence. Emerging data on DOACs are rapidly changing practice, requiring careful consideration of risks like bleeding and drug interactions to individualize therapy.
Do direct oral anticoagulants (DOACs) improve the treatment and prevention of cancer-associated thrombosis compared to LMWH or VKA in cancer patients?
Do direct oral anticoagulants (DOACs) improve the treatment and prevention of cancer-associated thrombosis compared to LMWH or VKA in cancer patients?
DOACs provide an effective oral alternative to LMWH for managing cancer-associated thrombosis, but require individualized patient selection due to bleeding risks.
Answers are grounded in this paper and cite their sources.
May support DOAC consideration for CAT convenience; leaves open dedicated cancer-specific RCTs.
Cancer-associated thrombosis (CAT) is a common occurrence in the journey of a cancer patient and its management poses significant challenges. Low molecular weight heparin (LMWH) is the standard of care but the high cost and the inconvenience of daily injections have led to low persistence with therapy. Direct oral anticoagulants (DOACs) are effective and safe for the treatment of venous thromboembolism (VTE) compared with vitamin K antagonist (VKA) therapy in noncancer patients, and emerging data comparing their use with LMWH in CAT are rapidly changing clinical practice. Recent randomized controlled trials also reported that specific DOACs are effective for primary prevention of CAT in patients undergoing systemic cancer therapy, but this benefit might be offset by an increased risk of bleeding. Undoubtedly, the option of an effective and safe oral anticoagulant is appealing to physicians and patients but critical limitations of DOACs, particularly bleeding and drug-drug interaction, need careful consideration. Understanding the scientific data, as well as each patient's preferences and values, are paramount in individualizing therapy in this special population of patients. This review summarizes the current evidence for DOACs for the treatment and prevention of CAT, discusses the importance of careful patient selection, and highlights upcoming new studies that will inform guideline recommendations.
No takes yet. Share an insight, caveat, or question.
Suryanarayan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: